Clinical trials
Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials
Below are recruiting recurrent or metastatic nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 2,385 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06202261RecruitingPhase 1/Phase 2
Study of TQB2930 for breast cancer that has returned or spread
This trial tests a new drug called TQB2930 alone or with other treatments for people with recurrent or metastatic breast cancer. It may help if you have a type of breast cancer called HER2-positive and have not had many prior treatments for advanced disease.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06236568Recruiting
Liver transplant study for liver cancer patients
This study tests a special way to preserve donated livers before transplant to see if it reduces the chance of liver cancer coming back after surgery.
Modena, MOAges 18 years+ - NCT06241612RecruitingPhase 3
Personalized neck radiation for nasopharyngeal cancer
This trial tests whether giving radiation only to the specific lymph nodes that need it works as well as standard radiation for people with nasopharyngeal cancer. It aims to reduce side effects while still controlling the cancer.
Guangzhou, GuangdongAges 18–70 - NCT06265025RecruitingPhase 1/Phase 2
GM103 injection for advanced solid tumors that can't be removed
This trial tests an experimental drug called GM103 that is injected directly into tumors. It is for people with advanced solid tumors that have not responded to other treatments and cannot be surgically removed.
Goyang-si, Gyeonggi-doAges 18 years+ - NCT06266338RecruitingPhase 2
Pembrolizumab and lenvatinib for recurrent or metastatic cervical cancer
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
Dallas, TexasAges 18 years+ - NCT06279364RecruitingPhase 3
Testing SKB264 vs standard chemo for advanced triple-negative breast cancer
This trial tests a new drug called SKB264 against standard chemotherapy options for people with advanced triple-negative breast cancer who have not yet received chemotherapy for their advanced disease. The goal is to see if SKB264 works better than the usual treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06292689RecruitingPhase 2
Cardunolizumab for advanced vulvar or vaginal cancer
This study is testing a new drug called cardunolizumab for people with advanced vulvar or vaginal cancer that has come back or spread. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18–75 - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Adelaide, South AustraliaAges 18 years+ - NCT06327269RecruitingEarly Phase 1
Targeted therapy after liver transplant for high-risk liver cancer
This trial tests a targeted therapy (lenvatinib) given after a living-donor liver transplant to prevent high-risk liver cancer from coming back. It is for people whose cancer is aggressive or did not respond well to previous treatments.
Kaohsiung CityAges 18–75 - NCT06367088RecruitingPhase 2
Combination drug therapy for advanced triple-negative breast cancer
This trial tests a new drug (cadonilimab) plus chemotherapy for people with advanced triple-negative breast cancer that has come back or spread. It aims to see if the combination works better than standard treatment.
Wuhan, HubeiAges 18–70 - NCT06387628RecruitingPhase 2
LM-108 with immunotherapy for advanced triple-negative breast cancer
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06390774RecruitingPhase 1
Study of SSGJ-705 for advanced cancers
This phase 1 trial tests a new targeted drug (SSGJ-705) for people with advanced solid tumors or lymphomas. Doctors will check safety and find the best dose, and there may be a chance the drug helps shrink or control the cancer.
Jinan, ShandongAges 18–75 - NCT06454578RecruitingPhase 2
Study of adebrelimab plus apatinib after liver cancer surgery
This trial is testing a combination of two drugs (adebrelimab and apatinib) after liver cancer surgery to see if it can lower the chance of the cancer returning. It is for people whose tumors had high-risk features.
Jinan, ShandongAges 18 years+ - NCT06459687RecruitingPhase 3
Socazolimab for first-line treatment of advanced cervical cancer
This phase 3 trial tests a new immunotherapy drug called socazolimab combined with chemotherapy as a first treatment for cervical cancer that has come back, spread, or cannot be removed with surgery or radiation. The goal is to see if it helps shrink tumors and improves survival.
Hefei, AnhuiAges 18–75 - NCT06467799RecruitingPhase 2
New drug combo before and after surgery for high-risk liver cancer
This trial tests giving a liver-directed chemotherapy (HAIC) plus an immunotherapy (PD-1) before surgery, followed by more immunotherapy after surgery, for people with a specific type of liver cancer that has a high chance of coming back. The goal is to see if this approach can reduce the risk of recurrence.
Guangzhou, GuangdongAges 18–75 - NCT06469281RecruitingPhase 1
A new immune cell therapy for recurring ovarian cancer
This early-phase trial tests a new immune cell therapy called 27T51, which targets a protein called MUC16 found on ovarian cancer cells. The study is for people with recurrent or treatment-resistant ovarian, primary peritoneal, or fallopian tube cancer to see if the therapy is safe and works when given alone or with other treatments.
Boston, MassachusettsAges 18 years+ - NCT06471673RecruitingPhase 1/Phase 2
BRIA-OTS cellular immunotherapy for metastatic breast cancer
This study tests an investigational cellular immunotherapy called BRIA-OTS for people with metastatic breast cancer that has spread and is no longer responding to standard treatments. It aims to help the immune system fight cancer cells.
Santa Monica, CaliforniaAges 18 years+ - NCT06472739RecruitingPhase 2
GM-CSF to prevent mouth sores during radiation for head and neck cancer
This study tests if a mouth rinse with GM-CSF (a protein that helps healing) can prevent mouth sores caused by radiation therapy for nasopharyngeal carcinoma. If you are about to start radiation, this may help reduce pain and trouble eating.
Guangzhou, GuangdongAges 18–65 - NCT06478693RecruitingPhase 1
Study of MT-303 for advanced liver cancer
This study tests a new drug called MT-303 for people with advanced liver cancer (HCC) or other cancers that produce a protein called GPC3. The drug is designed to target and attack the cancer cells. The trial is in an early phase, so it is looking at safety and how well the drug works.
Sydney, New South WalesAges 18 years+ - NCT06518564RecruitingPhase 2
Avelumab and M1774 for ARID1A-mutated endometrial cancer
This trial tests a combination of two drugs, avelumab (an immunotherapy) and M1774, in people with a specific type of endometrial cancer that has an ARID1A gene mutation. The goal is to see if this combination can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06537193Recruiting
Shorter MRI vs CT scan to check for liver cancer return
This trial compares a shorter MRI using a special dye to a CT scan for detecting liver cancer recurrence in people who have been cancer-free for at least two years after surgery or local treatment.
Seoul, Songpa-gu , 88, Olympic-ro 43-gilAges 20 years+ - NCT06561178Recruiting
Blood Test to Monitor Esophageal Cancer After Surgery
This trial looks at whether a personalized blood test can detect cancer returning after surgery for esophageal cancer. It tests people who had chemoradiotherapy before surgery and still had some cancer remaining in the removed tissue. The goal is to use the blood test to catch any remaining or returning cancer early.
Guangzhou, GuangdongAges Any age - NCT06577272Recruiting
Predicting cancer return after tumor ablation
This study looks at people with liver cancer who are treated with a procedure called radiofrequency ablation (RFA). It aims to create a tool that can predict the chance of the cancer coming back after treatment.
Hangzhou, ZhejiangAges Any age - NCT06616584RecruitingPhase 2/Phase 3
Cemiplimab plus standard care for advanced lung cancer after prior treatments
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
Daphne, AlabamaAges 18 years+
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 2,385 recruiting recurrent or metastatic nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent Nasopharyngeal Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Squamous Cell Carcinoma
- Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Metastatic Renal Cell Carcinoma
- Nasopharyngeal Carcinoma (NPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.